HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) Director Stuart B. Parker sold 25,000 shares of HealthEquity stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $96.72, for a total value of $2,418,000.00. Following the sale, the director now directly owns 19,061 shares in the company, valued at approximately $1,843,579.92. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
HealthEquity Trading Up 0.7 %
HQY opened at $95.62 on Monday. The stock has a market capitalization of $8.29 billion, a P/E ratio of 87.72, a P/E/G ratio of 1.10 and a beta of 0.55. HealthEquity, Inc. has a 12 month low of $62.10 and a 12 month high of $105.82. The firm’s fifty day simple moving average is $94.06 and its 200 day simple moving average is $84.26. The company has a current ratio of 3.20, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51.
Analyst Ratings Changes
A number of research analysts have commented on HQY shares. Bank of America raised their price target on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. BTIG Research lifted their target price on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada lifted their target price on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, The Goldman Sachs Group began coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 target price for the company. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, HealthEquity presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.71.
Institutional Investors Weigh In On HealthEquity
Several institutional investors have recently added to or reduced their stakes in HQY. SG Americas Securities LLC lifted its position in HealthEquity by 48.5% during the 2nd quarter. SG Americas Securities LLC now owns 3,798 shares of the company’s stock worth $327,000 after buying an additional 1,241 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of HealthEquity in the 2nd quarter valued at about $265,000. Gradient Investments LLC raised its holdings in shares of HealthEquity by 2.3% in the 2nd quarter. Gradient Investments LLC now owns 54,849 shares of the company’s stock valued at $4,728,000 after purchasing an additional 1,218 shares during the period. Raymond James & Associates raised its holdings in shares of HealthEquity by 11.3% in the 2nd quarter. Raymond James & Associates now owns 149,407 shares of the company’s stock valued at $12,879,000 after purchasing an additional 15,140 shares during the period. Finally, Vaughan Nelson Investment Management L.P. raised its holdings in shares of HealthEquity by 1.8% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 616,860 shares of the company’s stock valued at $53,173,000 after purchasing an additional 11,150 shares during the period. 99.55% of the stock is owned by institutional investors.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- How to Find Undervalued Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How Can Investors Benefit From After-Hours Trading
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.